Profile: Bristol-Myers Squibb Co (BMY)
17 Nov 2017
Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
The Company's Empliciti, a biological product, is a humanized monoclonal antibody for the treatment of multiple myeloma. Empliciti is approved for the treatment of multiple myeloma as combination therapy with Revlimid and dexamethasone in patients having received one prior therapy.
The Company's Opdivo, a biological product and designed to overcome immune suppression, is a human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and natural killer T (NKT) cells. Opdivo has received approvals for various indications, including melanoma, head and neck, lung, kidney and blood cancer. The Opdivo+Yervoy regimen also is approved in multiple markets for the treatment of melanoma. There are various registrational trials for Opdivo across other tumor types and other disease areas.
The Company's Sprycel is a multi-targeted tyrosine kinase inhibitor approved for the first-line treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Sprycel is also approved for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy, including Gleevec (imatinib mesylate).
The Company's Yervoy, a biological product, is a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma. The Company is evaluating Yervoy in a Phase III trial in stage III melanoma patients at risk of recurrence following complete surgical resection.
The Company's Eliquis is an oral Factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Eliquis is also targeted for the prevention and treatment of venous thromboembolic (VTE) disorders.
The Company's Orencia, a biological product, is a fusion protein with immunosuppressive activity targeted initially at adult patients with moderately to various active rheumatoid arthritis (RA). Orencia ClickJect Autoinjector is a self-administered autoinjector for adults with moderate to severe RA.
The Company's Baraclude is a selective inhibitor of hepatitis B virus. Baraclude is sold in the United States and International.
Hepatitis C Franchise
The Company's Daklinza (daclatasvir (DCV)) is an oral small molecule nonstructural protein 5A (NS5A) replication complex inhibitor for the treatment of hepatitis C virus infection (HCV) and is approved for use with Gilead Sciences, Inc.'s (Gilead) sofosbuvir. Its Sunvepra (asunaprevir (ASV)) is an oral small molecule nonstructural 3 protein (NS3) protease inhibitor for the treatment of HCV and is part of the dual regimen of DCV+ASV in Japan. Its Beclabuvir (BCV) is an oral small molecule non-nucleoside nonstructural protein 5B (NS5B) inhibitor for the treatment of HCV and is part of the triple combination tablet, Ximency, (DCV+ASV+BCV) in Japan.
The Company's Reyataz is a protease inhibitor for the treatment of HIV. The Reyataz Franchise includes Reyataz and combination therapy Evotaz (atazanavir 300 milligram (mg) and cobicistat 150 mg), a once-daily single tablet two drug regimen combining Reyataz and Gilead's Tybost (cobicistat) for the treatment of HIV-1 infection in adults.
The Company's Sustiva is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. The Sustiva Franchise includes Sustiva, an antiretroviral drug used in the treatment of HIV, as well as bulk efavirenz, which is included in the combination therapy Atripla (efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg), a once-daily single tablet three-drug regimen combining its Sustiva and Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate).
Bristol-Myers Squibb Co
345 PARK AVE
NEW YORK NY 10154
Company Web Links
- BRIEF-Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo
- BRIEF-Bristol-Myers and Syngene expand ongoing research collaboration
- BRIEF-Syngene International expands collaboration with Bristol-Myers Squibb
- BRIEF-Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study
- BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors